Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults

This interim analysis of an ongoing phase 1 randomized clinical trial evaluated the safety, reactogenicity, and immunogenicity of mRNA-1283, a next-generation SARS-CoV-2 messenger RNA (mRNA)-based vaccine encoding two segments of the spike protein (i.e. receptor binding and N-terminal domains). Heal...

Descripción completa

Detalles Bibliográficos
Autores principales: Yassini, Patrick, Hutchens, Mark, Paila, Yamuna D., Schoch, Lorraine, Aunins, Anne, Siangphoe, Uma, Paris, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Coronavirus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10128428/
https://www.ncbi.nlm.nih.gov/pubmed/37074202
http://dx.doi.org/10.1080/21645515.2023.2190690

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10128428/
https://www.ncbi.nlm.nih.gov/pubmed/37074202
http://dx.doi.org/10.1080/21645515.2023.2190690

Ejemplares similares